The Valley Desk

ArticleArthritis & rheumatology (Hoboken, N.J.)Published

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Hospital of the University of Pennsylvania, with Penn Medicine linked by the institution reference. Affiliation source

Publication record

Type
Article
Venue
Arthritis & rheumatology (Hoboken, N.J.)
Published
PubMed ID
42473780
Added to directory
Source checked

Report a correction or request removal